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Abstract: This scoping review provides new evidence on the prevalence and patterns of global
antimicrobial use in the treatment of COVID-19 patients; identifies the most commonly used antibi-
otics and clinical scenarios associated with antibiotic prescribing in the first phase of the pandemic;
and explores the impact of documented antibiotic prescribing on treatment outcomes in COVID-19
patients. The review complies with PRISMA guidelines for Scoping Reviews and the protocol is
registered with the Open Science Framework. In the first six months of the pandemic, there was a
similar mean antibiotic prescribing rate between patients with severe or critical illness (75.4%) and
patients with mild or moderate illness (75.1%). The proportion of patients prescribed antibiotics
without clinical justification was 51.5% vs. 41.9% for patients with mild or moderate illness and
those with severe or critical illness. Comparison of patients who were provided antibiotics with
a clinical justification with those who were given antibiotics without clinical justification showed
lower mortality rates (9.5% vs. 13.1%), higher discharge rates (80.9% vs. 69.3%), and shorter length
of hospital stay (9.3 days vs. 12.2 days). In the first 6 months of the pandemic, antibiotics were
prescribed for COVID-19 patients regardless of severity of illness. A large proportion of antibiotic
prescribing for mild and moderate COVID-19 patients did not have clinical evidence of a bacterial
co-infection. Antibiotics may not be beneficial to COVID-19 patients without clinical evidence of a
bacterial co-infection.
Keywords: COVID-19 patients; disease severity; antibiotic use; clinical justification; secondary
infections
1. Introduction
Antimicrobial resistance (AMR) kills an estimated 700,000 people every year [1].
Without intervention, the current trajectory predicts a gloomy figure of 10 million fatalities
by 2050 [2]. The SARS-CoV-2 pandemic foreshadows the crisis of living with an infectious
disease for which there is no treatment and the damaging consequences to our health
systems and economies. At the beginning of the pandemic, with the panic of facing the
unknown, many existing medicines were repurposed to treat the virus. This included
widespread use of antibiotics in treatment [3–7]. For example, in a multi-hospital cohort
study in the USA, 56.6% of 1705 patients were prescribed early empiric antibacterial therapy,
of which only 3.5% were confirmed to have bacterial infection [5]. Two systematic reviews
found that, of the patients reported in the included studies, 72.0% received antibiotics,
and 14.3% suffered a secondary bacterial infection [4,7]. The low proportion of COVID-19
patients having co-infection or secondary infection in these studies is consistent with other
findings. For example, in Italy, from the 16,654 patients who died of COVID-19, only
11% were reported to have a secondary bacterial infection (data as of 9 April 2020) [8]. In
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Spain, of 989 consecutive patients with COVID-19, only 72 (7.3%) had confirmed bacterial
infections [9].
Overall, the pandemic may be accelerating the threat of AMR due to the increased use
of antibiotics, increased exposure to hospital environments and invasive procedures used in
COVID-19 treatment, while evidence for the benefits of antimicrobial use in such patients
is limited. Many AMR experts have raised their concerns around the safety of using
antibiotics in COVID-19 patients and called for strengthening antimicrobial stewardship
(AMS) programs in the time of COVID-19 [8,10–14]. For example, the increased use
of empirical antibiotics treatment increases the risks of Clostridioides difficile infection in
COVID-19 patients and the emergence of multidrug resistant organism [15,16].
Guidelines have started to emerge around the use of antimicrobials in COVID-19
patients. For example, WHO guidelines recommend no antibiotic therapy or prophylaxis
for patients with mild or moderate COVID-19 unless signs and symptoms of a bacterial
infection exist. For severe COVID-19, a daily assessment for de-escalation of antimicrobial
treatment is recommended. For elderly patients and children under five with moderate
COVID-19, WHO recommends use of antibiotics categorized in the WHO access list of
medicines such as co-amoxicillin [10,17].The March 2021 UK National Institute for Health
and Care Excellence (NICE) rapid guideline on managing COVID-19 provides the following
consensus recommendations: (1) do not use antibiotics for preventing or treating COVID-
19; (2) only use antibiotics if there is a strong clinical suspicion of additional bacterial
infection [18]. Other guidelines such as those of the Dutch Working Party on Antibiotic
Policy [16] and the Scottish Antimicrobial Prescribing Group [19] both advise avoiding
routine antibiotic use in suspected COVID-19, the importance of obtaining sputum and
blood samples as well as urinary antigen testing upon admission, and a cautious antibiotic
treatment of short duration of five days in patients of COVID-19 when there is a clinical
suspicion of secondary bacterial infection.
There is an urgent need for further research and guidance in this field, from producing
evidence-based guidelines [16], reassessing biomarkers for antimicrobial stewardship in
COVID-19 patients [13], understanding drivers, benefits, and disbenefits of antibiotic use,
and assessing the wider impact of the pandemic on antimicrobial use (AMU) and AMR. In
this scoping review, we aim to: add to the research evidence on prevalence and patterns of
antimicrobial use in the treatment of COVID-19 patients; identify the most commonly used
antibiotics and clinical scenarios associated with AMU; and to explore any impact of AMU
on patient treatment outcomes.
2. Results
2.1. Study Selection
A total of 1216 records were identified through database searching. After duplicates
were removed and irrelevant records of COVID-19 research not related to clinical treat-
ment of COVID-19 patients were excluded, 223 records were screened for eligibility. A
further 113 studies that reported neither antimicrobial use in treatment nor patients with
co-infections were excluded. The remaining 110 articles and an additional eight articles
that were identified by searching the reference lists of the retrieved articles and the au-
thors’ reference collections, led to a total of 118 full-text articles being included for review
(Figure 1).
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2.2. Description of Included Studies
Of 118 included studies, 59 were case series or case reports, 47 were observational
studies (all types of observational study xcept c hort studies), seven w re randomized
controlled trial , and five were cohort studies. M st of th studi s ere co ucted in
low- an middle-income countries, consonant wi h the trajectory of the pandemic at that
stage, with the ajority conducted in China (51.7%), f llowed by USA Italy and Fr nce
(Supple entar Table S1). Hig est number of studies were from East Asia and Pacific
(55.9%), followed by Europe and Central Asia (22.0%) and North America (14.4%). All
the studies rep rted data of hospit lized COVID-19 patients. There were no reports of
non-hospitalized COVID-19 patients in our results.
2.3. Antibiotic Prescribing and Illness Severity
Severity of illness was not report d in all studies. Just over half reported the severity
of illness using four categories (severe, critical, moderate, and mild) and the rest remainder
used three groups (severe, moderate, and mild). In order to explore the potential role of
severity of illness in decisions regarding antibiotic prescribing, we grouped severity of
illness into two broader categories: severe or critical, and moderate or mild. A total of
2630 patients (41.9%) fell into the severe or critical group and 3649 patients (58.1%) into
mild or moderate group.
In the included studies, 8501 out of 10,329 COVID-19 patients (82.3%) were prescribed
antibiotics. There was little difference in the mean rates of antibiotic prescribing with 75.4%
in severe or critical vs. 75.1% in mild or moderate groups (Table 1).
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Table 1. Severity of illness and antibiotic prescribing.
Illness Severity of
COVID-19 Patients Patient Size n (%)
Mean Antibiotic Prescribing
(%)
Severe and critical patients 2630 (41.9) 75.4
Mild and moderate 3649 (58.1) 75.1
Total 6279 (100.0) 75.2
2.4. Antibiotic Prescribing and Health Outcomes
We further explored the relationship between antibiotic prescribing and health out-
comes (length of hospital stay (LOS), discharge rate, and mortality rate (all these health
outcomes were calculated at the time of publication of those studies; some patients were
still in hospital and these patients were not included in their calculation). The results show
that patient mortality was higher in studies for patients all given antibiotics compared
to studies that majority of patients were not given antibiotics (26.5% vs. 2.3%), LOS was
longer (12.5 days vs. 10.3 days), and discharge rate was also higher (76.2% vs. 73.2%)
(Table 2).
Table 2. Antibiotic prescribing categories and outcomes.





1 All given abs (58 studies) 12.5 76.2 26.5
2 Majority are given abs (37 studies) 14.3 57.9 13.1
3 Majority not given abs (11 studies) 10.3 73.2 2.3
2.5. Frequently Prescribed Antibiotics
We extracted the details of prescribed antibiotics from all the included studies where
this information was available. Further, 33.9% of included studies did not report the
details of antibiotics but only mentioned that antibiotics or empirical antibiotics were used
in treatment.
Among the 78 studies that reported type of antibiotics used in the treatment of COVID-
19 patients, (Figure 2) azithromycin (macrolides and ketolides) was the most frequently
prescribed antibiotic (accounting for 28.0% of studies); followed by ceftriaxone (17.8%), moxi-
floxacin (14.4%), meropenem (14.4%), and Piperacillin/tazobactam (12.7%). It is not possible
to tabulate prescribing percentages of these frequently prescribed antibiotics for the treatment
of hospitalized COVID-19 patients as most studies, except case report or case series, did not
report the percentage of each prescribed antibiotic in the treatment of COVID-19 patients.
Notably, the frequently prescribed antibiotics are all broad-spectrum antibiotics.
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2.6. Antibiotic Prescribing Scenarios
We summarized 20 different scenarios when antibiotics were prescribed based on the
evidence available in our included studies (Table 3). We asked two experienced clinicians
in infectious diseases with expertise in AMS practices to classify each antibiotic prescribing
scenario as: (1) with clinical justifications; (2) without clinical justifications; (3) not sure. In
addition to microbiological analysis; sepsis, elevated white blood cells or procalcitonin are
also signs of bacterial infection and antibiotics prescribed under those circumstances were
considered as “with clinical justifications”. There were some ambiguous cases (around
30% of scenarios) on which both experts found difficult to make judgements regarding
whether antibiotics should be prescribed or not; we categorized those as “not sure”. A
relatively high proportion (around 45%) of scenarios described in the included studies
were categorized by both experts as “without clinical justifications”.
Table 3. Antimicrobial prescribing scenarios of hospitalized COVID-19 patients.
Antimicrobial Prescribing Scenarios
with Clinical Justifications (A)
Antimicrobial Prescribing Scenarios without
Clinical Justifications (B)
Antimicrobial Prescribing Scenarios not Sure
whether with or Without Clinical Justifications (C)
Scenario 1: Microbiological analysis
such as blood, stool, urine, or sputum
culture was tested positive.
Scenario 4: Respiratory failure such as acute
respiratory distress syndrome (ARDS)
Scenario 9: Patients are older or frail, or have a
pre-existing comorbidity such as immunosuppression
(Solid organ transplant recipients who remain on long
term immune suppression therapy), HIV patients, or
significant heart or lung disease (for example
bronchiectasis or COPD, systemic lupus
erythematosus), or have a history of severe illness
following previous lung infection
Scenario 2: Pulmonary aspergillosis Scenario 7: C reactive protein higher (around30 mg/L, normal range 0–8 mg/L)
Scenario 10: Elder patient with other type of cancer not
listed above, diabetes, hypertension
Scenario 3: Septic shock or sepsis Scenario 8: Patients received ventilation ormechanical ventilation
Scenario 12: Azithromycin was used as a combination
therapy with hydroxychloroquine
Scenario 5: Procalcitonin >0.5 ng/mL Scenario 11: Pregnant woman for caesareansection, or with suspected bronchitis
Scenario 14: Mentioned that “Abs were used as an
empirical treatment when it was very difficult to
exclude bacterial co-infection”; or “abs were used if
needed and this decision was based on health care
providers’ discretion” or “abs were initialled at the
beginning but was discontinued after COVID-19 was
confirmed or after microbiological culture analysis
tested negative” or “abs were empirically used and
patient developed bacterial infection later (case report)
or a high percentage of patients developed bacterial
co-infections later
Scenario 6: a high percentage of
neutrophils (neutrophilia), WBC count
Scenario 13: Antimicrobial treatment was
given without any justifications (Not reporting
any suspected bacterial/fungal co-infection
symptoms, or any lab test results indicating
possible bacterial/fungal infections)
Scenario 15: Abs were used for most patients (higher
prescribing rate) to cover possible bacterial
co-infections; however only a minor percentage of
patients developed bacterial/fungal infections
Scenario 18: Paediatric patient (infant,
preterm neonate) with abnormal
blood cell test or CRP levels; or
suspected sepsis etc
Scenario 16: Abs were reported to be used as
an empirical/adjuvant/concomitant/standard
treatment; and patients were given abs on
admission, or before randomization into
different trial groups for some trials)
Scenario 17: Dual or triple antibiotics used
Scenario 19: Patient with acute appendicitis
Scenario 20: Patient with digestive symptoms
We also categorized the frequency of each antibiotic prescribing scenario by illness
severity (Supplementary Table S2). We found that only 12.9% of severe or critically ill
patients were prescribed antibiotics with clinical justifications, and this proportion was
13.6% for mild or moderate patients. The proportion of patients prescribed antibiotics
without clinical justification was 51.5% vs. 41.9% for patients with mild or moderate illness
and those with severe or critical illness.
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2.7. Severity of Illness, Antibiotic Prescribing Justifications, and Health Outcomes
All studies with all severe or critical patients had a higher mortality rate than all
studies with mild or moderate patients (53.1% vs. 0.2%), similarly with lower discharge
rate (96.2% vs. 36.6%) and higher LOS (17.4% vs. 8.7%) (Table 4).
Table 4. Severity of illness and health outcomes.
Severity of Illness (Categories) LOS (Mean Days) Discharge (Mean%) Mortality (Mean%)
All severe/critical (16 studies) 17.4 36.6 53.1
Majority were severe/critical (4 studies) 18.0 77.9 5.8
Majority were mild/moderate (33 studies) 12.0 60.5 4.8
All mild/moderate (20 studies) 8.7 96.2 0.2
Mortality rate was lower for those patients who were provided antibiotics with clinical
evidence of infections compared to those who were given without clinical justifications
(9.5% vs. 13.1%), discharge rate was higher (80.9% vs. 69.3%) and LOS was lower (9.3 days
vs. 12.2 days) (Table 5).
Table 5. Antibiotic prescribing justifications and health outcomes.
Antibiotic Prescribing Justified or Not LOS (Mean Days) Discharge (Mean%) Mortality (Mean%)
A-with clinical justifications” (n = 14) 9.3 80.9 9.5
B-without clinical justifications (n = 49) 12.2 69.3 13.1
C-not sure (n = 47) 14.1 61.1 24.8
2.8. Secondary Infections and Health Outcomes
Nine of the 118 studies reported on secondary infections. Out of a total sample size
of 820 in these studies, 74.4% patients had diagnosed secondary infections (n = 610) and
51.3% of these patients were serious or critically ill (n = 313). In perspective to our total
sample size across all studies (6279 patients), the percentage of patients with confirmed or
diagnosed secondary infections was 9.7%. Compared to total patients (n = 6279), patients
with secondary infections had higher LOS (20.4 days vs. 12.4 days), lower discharge rate
(54.8% vs. 65.6%), and higher mortality rate (43.7% vs. 16.3%) (Table 6).














infections (n = 610)
313 (51.3%) 297 (48.7%) 20.4 54.8 43.7
Total sample size
(n = 6279) 2630 (41.9%) 3649 (58.1%) 12.4 65.6 16.3
2.9. Gender and Health Outcomes
We found that male patients compared to female patients had a higher mortality rate
(37.7% vs. 20.0%), lower discharge rate (75.2% vs. 91.7%), and longer LOS (13.4 days vs.
11.4 days) (Supplementary Table S3). These findings are in line with other recent studies
conducted with COVID-19 patients across the world [20,21].
2.10. Study Design and Country Economic Status
We conducted a stratified analysis of antibiotic prescribing rate, length of hospital
stay, discharge rate, and mortality rate by study design and incomes of the countries
where studies originated. There was little variation in antibiotic prescribing rate, length of
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hospital stay, and discharge rate by study design. The highest mortality rate was reported in
cohort studies (25%) and lowest reported in randomized control trials (3%) (Supplementary
Table S4). Reported antibiotic prescribing rates, length of stay, and mortality rates were
also similar between low-and-middle income countries (LMICs) and high-income countries
(HICs) based on World Bank Classfication. However, discharge rates were considerably
lower in LMICs (60.2%) compared to HICs (81.9%) (Supplementary Table S5).
3. Discussion
As the numbers of people with COVID-19 continue to increase globally, the widespread
use of antibiotics for the treatment of COVID-19 patients and the potential consequences of
this for AMR are a growing concern.
Our included studies provide data on patients in hospital settings; this was not an
inclusion criterion but none of the studies identified presented data on non-hospitalized
patients (e.g., care home patients, patients in the community, or treated as outpatients).
This is probably because data outside hospital settings are harder to obtain and were not
explored in the first six months of the pandemic. Data synthesis from the 118 studies
included in this review shows that around 82.3% of hospitalized COVID-19 patients were
prescribed antibiotics, whereas antibiotic prescribing percentages of COVID-19 patients
were almost 100% in the early clinical reports from hospitals in Wuhan [22–24]. It is
unsurprising that doctors were giving antibiotics almost universally to treat this previously
unknown respiratory infection at the beginning of the pandemic; resort to antibiotics
would be expected to decline with increasing knowledge about the novel coronavirus.
More surprisingly, the antibiotic prescribing rate does not vary with illness severity (75.4%
in severe or critical vs. 75.1% in mild or moderate patients).
Antibiotics use may be warranted in managing COVID-19 patients with suspected
bacterial co-infections and severe/critically ill patients with increased risks of developing
bacterial co-infections due to long hospital stays or immunosuppression [18]. Differen-
tiating bacterial secondary co-infection from severe COVID-19 inflammatory reaction is
clinically difficult, and commencing empirical antibiotic therapy in these circumstances
is understandable. COVID-19-related concerns or unknowns may change prescription
behaviors of healthcare professionals (HCPs) and drive antibiotic use [25]. Additionally,
diagnostic confirmation of secondary bacterial/fungal infections through microbiological
culturing is costly, time consuming, and not available in smaller hospitals, making rapid
exclusion of secondary infections very difficult and pushing HCPs to err on the side of
treating with antibiotics both as directed and empirical therapy.
Previous experience of viral respiratory infection may also have played a role; for
example, in the USA, 30% of critical ill patients had bacterial co-infections in the 2009
influenza A (H1N1) pandemic [26], while around 23% of severe influenza patients had
bacterial co-infections in the 2013–2014 flu season [27]. In contrast, evidence reviewed by
NICE up to March 2021 [18] suggests that less than 8% of people with COVID-19, and as
few as 0.1% of hospitalized patients, have bacterial co-infections, but it is understandable
that rates similar to those seen in influenza may have been assumed initially in COVID-19
patients.
However, the high rates of antibiotic prescribing for mild or moderate COVID-19
patients (around 51.5% of whom were given antibiotics suggests more indiscriminate use in
the absence of clinical evidence for possible bacterial co-infection. Antibiotic prescribing for
mild and moderate COVID-19 patients is inconsistent with WHO COVID [17] and recently
updated UK NICE guidelines [18] and not only indicates the emerging challenges of
antimicrobial stewardship practice in hospitals around the world, but suggests a potential
increase in resistant bacterial pathogens in affected countries.
Moreover, the antimicrobials found to have been most frequently prescribed in this
review (azithromycin, ceftriaxone, moxifloxacin, meropenem, piperacillin/tazobactam) are
all classified as critically important antimicrobials (CIA) for human medicine [28]. Persis-
tent use of these critically important antibiotics will provoke the emergence of MDR strains
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and a decline in the effectiveness of these compounds [29], posing a threat to survival
rates from serious infections, neonatal sepsis, and hospital infections, thus limiting the
potential health benefits of surgery, transplants, and cancer treatment [30]. A systematic
review has provided evidence on the emergence of AMR after mass azithromycin distribu-
tion for trachoma control programmes in Sub-Saharan Africa; macrolide resistance after
azithromycin distribution was reported in three of the five organisms studied and there
was little evidence for absence of resistance in Chlamydia trachomatis after azithromycin
treatment, suggesting that azithromycin may not remain effective for future trachoma
programmes [31]. The impact of widespread use of ceftriaxone on development of resis-
tance to third generation cephalosporins among clinical strains of Enterobacteriaceae and
other non-enteric bacteria is already well known [32–34]. If resistance to azithromycin,
ceftriaxone, and other broad-spectrum antibiotics becomes widespread due to their massive
use during the pandemic, there would be very few alternative antibiotics available in the
market and these alternatives antibiotics are likely to be unaffordable for the majority of
patients, especially in low and middle-incomes countries.
The low proportion of antibiotic prescribing (less than 14%) for COVID-19 patients
with a clinical justification for assuming the presence of bacterial infection provides further
evidence that clinical indication was not the primary driver of antibiotic therapy. Overall,
40–50% of antibiotic prescribing (41.9% for severe or critical patients vs. 51.5% for mild or
moderate patients) in the included studies occurred without clinical indications of bacterial
infection. Around 45% of antibiotic prescribing scenarios described in the reviewed studies
were classified as “not sure” for severe or critical patients, but only around 35% for mild
or moderate patients, suggesting that in cases of greater severity, HCPs are more likely
to resort to antibiotic treatment even in the absence of clinical indications suggestive of
bacterial infection. Only 9.7% of all COVID-19 patients with documented severity status in
the reviewed studies were reported to have a secondary bacterial infection, consistent with
findings from other publications [3,4]. Among the three most common prescribing scenarios
reported in our included studies (Supplementary Table S3), two involved unwarranted
antibiotic prescribing.
Our analysis also provides evidence regarding the effect of antibiotic use on treatment
outcomes, as measured by LOS, discharge rate, and mortality rate of hospitalized COVID-
19 patients. We found that overall, patients who were provided antibiotics with a clinical
justification compared with those who were given antibiotics without clinical justification
showed lower mortality rates (9.5% vs. 13.1%), higher discharge rates (80.9% vs. 69.3%),
and shorter length of hospital of stay (9.3 days vs. 12.2 days). This evidence supports and
strengthens the rationale for current guidance that COVID-19 patients without a confirmed
or suspected (based on clinical/microbiological indicators) secondary infection should
not be prescribed antibiotics. This is consonant with findings from a retrospective study
examining treatment outcomes in 1123 COVID-19 patients from Wuhan that compared
antibiotics treatment between patients with suspected bacterial infection compared to
those with no evidence of bacterial infection. Antibiotic therapy including penicillin and
meropenem treatment was found to be associated with increased mortality in patients
with no evidence of bacterial infection and the authors concluded that most patients
without suspected bacterial infection would not benefit from antibiotics treatment [35].
A retrospective study that reviewed the medical charts of 48 intubated ICU patients
admitted between April and May 2020 in Switzerland, also reported that early administered
antibiotics do not appear to significantly impact mortality or delay hospital-acquired
infections in critically ill COVID-19 patients [36].
Although empirical, adjuvant, and prophylactic use of antibiotics for severe and
critical patients is still endorsed in WHO and China guidelines [17,37], this may not confer
the expected benefits. Our results suggest that antibiotic treatment may not improve
COVID-19 patients’ treatment outcomes. Patients who were prescribed antibiotics with
suspected bacterial infection were also more likely to have negative clinical outcomes,
including higher LOS (20.4 days vs. 12.4 days), lower discharge rate (54.8% vs. 65.6%), and
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higher mortality rate (43.7% vs. 16.3%) compared to average patient treatment outcomes.
Large multi-center studies are urgently needed to provide direct evidence for our findings
and further investigate the impact of antibiotic treatment on mortality and other treatment
outcomes of COVID-19 patients with different illness severities.
Strengths of this review include coverage of 118 studies across a wide range of study
designs published during the six-month review period, giving a full landscape of the
prevalence and patterns of antibiotic prescribing for COVID-19 patients in hospital settings
during the first wave of the pandemic. Although more is now known about COVID-19
and effective treatments, as it spreads across the globe, there is no reason to believe that
antibiotics are not still being used widely, particularly in more recently affected low and
middle-income countries with limited resources, so our findings continue to have relevance.
The review also has several inevitable limitations. First, we relied on published online
research article searching in selected databases; this may result in publication bias. Second,
we excluded studies not available in English or Chinese, which may cause language bias
as we were not able to include studies from European countries that were published in
local languages. Third, the severity classifications given in the included papers varied
between studies: just over half reported severity of illness using four categories (critical,
severe, moderate, and mild) and the remainder used three groups (severe, moderate, and
mild). This necessitated merging patients with reported illness severity into just two
groups (severe or critical, and moderate or mild) in our analysis. Our findings concerning
relationships between illness severity, antibiotic prescribing, and treatment outcomes
should therefore be treated with caution. Finally, we did not assess the quality of the
included studies and were unable to conduct meta-analysis due to the heterogeneity of the
studies under review. This may result in less robust and generalizable findings. However,
the inclusion of a wide range of study designs helps to provide a more complete picture of
global antibiotic prescribing patterns during the COVID-19 pandemic than is available in
the current scientific literature.
4. Materials and Methods
This rapid review was undertaken to identify, synthesize, and analyze findings from
studies that reported antibiotic use in the treatment of COVID-19 patients. The review was
conducted to comply with PRISMA guidelines for Scoping Reviews (http://www.prisma-
statement.org/Extensions/ScopingReviews accessed on 9 June 2020) [38]; and the protocol
was registered with the Open Science Framework (OSF): http://osf.io/vp6t5 (accessed on
23 July 2020). We selected a scoping rather than systematic review approach in order to
maximize data inclusion from a wide range of study types.
4.1. Search Strategy
The following databases: Web of Science, EMBASE, PubMed, and two Chinese aca-
demic databases (CNKI and VIP) were searched to identify relevant studies from 1 Dec
2019 up to 15 June 2020; no limits were set on the country where study was conducted,
and we excluded any studies not available in English or Chinese. The search terms were:
((“COVID-19” or “SARS-CoV-2” or “Coronavirus disease 2019” or “severe acute respiratory
syndrome coronavirus-2”) and ((“antibiotic prescribing” or “antibiotic use” or “antibiotic*”)
or “antimicrobial *” or “antimicrobial therapy” or “antimicrobial resistance” or “antimicro-
bial stewardship”)).
4.1.1. Web of Science
All Fields = (COVID-19 and antibiotic*) or (SARS-CoV-2 and antibiotic*) or (Coron-
avirus disease 2019 and antibiotic*) or (severe acute respiratory syndrome coronavirus-2
and antibiotic*)
All Fields = (COVID-19 and antimicrobial*) or (SARS-CoV-2 and antimicrobial*) or
(Coronavirus disease 2019 and antimicrobial*) or (severe acute respiratory syndrome
coronavirus-2 and antimicrobial*)
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4.1.2. PubMed
(COVID-19 or SARS-CoV-2 or Coronavirus disease 2019 or severe acute respiratory
syndrome coronavirus-2) and antimicrobial*
(COVID-19 or SARS-CoV-2 or Coronavirus disease 2019 or severe acute respiratory
syndrome coronavirus-2) and antibiotic*
4.1.3. Embase
(antibiotic* or antibiotic prescribing or antimicrobial resistance or antibacterial*) and
(severe acute respiratory syndrome coronavirus-2 or COVID-19 or SARS-CoV-2 or Coron-
avirus disease 2019).
4.1.4. CNKI and VIP
(COVID-19 or SARS-CoV-2 or Coronavirus disease 2019 or severe acute respiratory
syn-drome coronavirus-2) and (antibiotic* or antibiotic use or antimicrobial resistance or
antibacterial*)
4.2. Inclusion, Exclusion Criteria, and Study Selection Process
Articles fulfilling the following criteria were considered for inclusion in the review.
Full-text articles only were included.
4.2.1. Inclusion criteria
1. All types of clinical studies (randomized control trial (RCT), cohort, case report
including case series, other observational studies (except cohort)) about the use of
antibiotics to treat patients with COVID-19.
2. Studies reporting patients diagnosed with COVID-19 and receiving antibiotic treat-
ment, without restrictions on age, race, gender, geographical location.
3. Studies which had mentioned antibiotic treatment and also reporting treatment
outcomes.
4. Studies reporting COVID-19 patients with bacterial co-infections.
4.2.2. Exclusion Criteria
1. Animal studies, in vitro experiments, in silico screening/drug modeling, molecu-
lar mechanism, and other aspects of COVID-19 research where not related to or
mentioned antibiotic use (ABU).
2. Conference abstracts.
3. Commentaries and editorial letters not reporting ABU.
4. Literature review not reporting ABU.
5. Trial protocol.
6. Case report and case series not reporting ABU.
7. Full-text articles not available in English or Chinese.
8. Studies reporting suspected or asymptomatic COVID-19 patients.
9. Studies reporting COVID- 19 patients in primary care settings such as GP and com-
munity health center.
Titles and abstracts were screened initially, and full texts were retrieved of articles
which appeared to fulfil the inclusion criteria. Two independent, duplicate screenings were
undertaken by WC and NA for all search results. Disagreement was resolved by consensus.
Additional studies were identified by searching the reference lists of retrieved articles and
the authors’ reference collections.
4.3. Data Extraction
A bespoke data extraction form was developed and validated through two indepen-
dent, duplicate extraction of data from five relevant studies. Data extraction for antibiotic
use in the treatment of COVID-19 patients included: publication details, region, type of
COVID-19 patients, age, gender, number of patients reported, study type (case report
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including case series, RCT, cohort, other observational studies), type of patients (mild
or moderate, severe, or critical), antimicrobial prescribing rate (overall and for different
types of patient, details of antibiotics prescribed if reported, antibiotic prescribing scenarios
(under which circumstance antibiotic was prescribed), whether antibiotic treatment had
complied with AMS practice (yes, no, or not sure), mean length of hospital stay, discharge
rate, and mortality rate.
Data extraction for COVID-19 patients with secondary bacteria or fungal infections in-
cluded: publication details, region, gender, reported number of patients with co-infections,
type of patients with co-infections (severe or critical ill), type of co-infections, details of
antibiotic used for the treatment of co-infections, length of stay, discharge rate, mortality
rate of patients with co-infections, gender, age, and underlying health conditions of patient
with co-infections if reported.
4.4. Data Synthesis and Analysis
We looked at the overall antibiotic prescribing rate, scenarios of antibiotics prescribing,
types of antibiotic use, and health outcomes of patients. In this review, data extraction and
analysis were performed in Microsoft Excel. We conducted descriptive synthesis, taking
into account of the sample size of each study (i.e., weighted mean) while calculating pooled
estimates of outcome variables (i.e., antibiotics prescribing%, mortality rate, discharge
rate, length of stay). We also conducted subgroup analyses of COVID-19 patients who
were given antibiotics during hospital admission, most frequently used antibiotics for
these patients, mean percentage of clinically justifiable antibiotic use, most frequently used
medicines (other than antibiotics) for COVID-19 patients, proportion of COVID-19 patients
having underlying health conditions, mean length of stay in hospital, mean discharge
rate, and mean mortality rate. In addition, we also conducted stratified analysis of major
outcome variables (antibiotic prescribing rate, length of hospital stay, discharge rate, and
mortality rate) by type of study design and income of originating country. The studies
were divided into two major income groups (High-Income Countries and Low-and-Middle
Income Countries) using World Bank classification [39]. We also classified the region of
origin of all included studies using the World Bank classification into seven groups, as
reported in the Supplementary Table S1.
As described above, we also investigated proportion of patients experiencing co-
infections (fungal, bacterial, or other), most frequently used antibiotics for the treatment
of co-infections, mean length of stay for patients with co-infections, mean discharge rate
and mean mortality rate for the patients with co-infections, and proportion of patients
with co-infection having underlying health conditions. We present these results by age and
gender of patients.
5. Conclusions
This review and evidence synthesis suggest that during the first six months of the
COVID-19 pandemic, antibiotic prescribing in hospitals was not associated with illness
severity. A large proportion (40–50%) of antibiotic prescribing for COVID-19 patients did
not have clinical indications of a bacterial co-infection; around half of COVID-19 patients
with mild or moderate illness, had been prescribed antibiotics in the reports and studies we
reviewed. Patients without clinical evidence of a bacterial co-infection should not receive
antibiotics treatment according to international guidelines.
The evidence reviewed suggests that where secondary bacterial infection is absent,
antibiotic prescribing may not be beneficial to treatment outcomes for COVID-19 patients.
Until more clinical data become available to verify these findings, considerable caution is
warranted when considering antibiotic treatment in COVID-19 cases, even for severe and
critically ill patients. The widespread use of antibiotics for COVID-19 may not only magnify
the problem of antibiotic resistance globally and render currently available antibiotics
ineffective, but also provide little or no benefit for COVID-19 patients. A further scoping
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review to capture changes in global prevalence and patterns of antibiotic prescribing for
COVID-19 patients in hospital settings from June 2020 to Aug 2021 is currently underway.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/antibiotics10060745/s1, Supplementary Table S1: Description of included studies; Supple-
mentary Table S2: Severity of illness and scenario of antibiotic prescribing; Supplementary Table S3:
Types of study based on gender and health outcomes (LOS, discharge and mortality); Supplementary
Table S4: Antibiotic prescribing, length of stay, discharge rate and mortality rate by study designs;
Supplementary Table S5. Antibiotic prescribing, length of stay, discharge rate and mortality rate by
income of the study countries. Annex 1 References list included for this review.
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